The stock of Cytokinetics, Inc. (NASDAQ:CYTK) is a huge mover today! The stock increased 10.31% or $0.91 during the last trading session, hitting $9.74. About 1.39M shares traded hands or 356.15% up from the average. Cytokinetics, Inc. (NASDAQ:CYTK) has risen 35.43% since March 28, 2016 and is uptrending. It has outperformed by 30.72% the S&P500.
The move comes after 6 months positive chart setup for the $383.24M company. It was reported on Oct, 28 by Barchart.com. We have $13.44 PT which if reached, will make NASDAQ:CYTK worth $145.63M more.
Analysts await Cytokinetics, Inc. (NASDAQ:CYTK) to report earnings on November, 3. They expect $-0.31 EPS, down 34.78% or $0.08 from last year’s $-0.23 per share. After $-0.29 actual EPS reported by Cytokinetics, Inc. for the previous quarter, Wall Street now forecasts 6.90% negative EPS growth.
Cytokinetics, Inc. (NASDAQ:CYTK) Ratings Coverage
Out of 6 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 6 analyst reports since July 24, 2015 according to StockzIntelligence Inc. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. The firm has “Outperform” rating by FBR Capital given on Tuesday, November 10. As per Monday, November 9, the company rating was maintained by Roth Capital. The stock of Cytokinetics, Inc. (NASDAQ:CYTK) has “Buy” rating given on Friday, July 24 by MLV. As per Wednesday, July 27, the company rating was maintained by Needham. The firm earned “Buy” rating on Monday, November 9 by TH Capital.
According to Zacks Investment Research, “Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.”
Insitutional Activity: The institutional sentiment decreased to 0.46 in Q2 2016. Its down 0.08, from 0.54 in 2016Q1. The ratio fall, as 19 funds sold all Cytokinetics, Inc. shares owned while 37 reduced positions. 8 funds bought stakes while 18 increased positions. They now own 26.30 million shares or 0.76% less from 26.50 million shares in 2016Q1.
Blackrock Advisors Limited Liability accumulated 121,700 shares or 0% of the stock. Jacobs Levy Equity Mgmt has invested 0% of its portfolio in Cytokinetics, Inc. (NASDAQ:CYTK). Geode Mngmt Ltd Com has 271,851 shares for 0% of their US portfolio. Clarivest Asset Ltd Llc reported 89,263 shares or 0.03% of all its holdings. Panagora Asset Management holds 0% or 76,805 shares in its portfolio. Morgan Stanley accumulated 0% or 7,643 shares. State Street reported 623,246 shares or 0% of all its holdings. Parametric Portfolio Assoc Lc has invested 0% of its portfolio in Cytokinetics, Inc. (NASDAQ:CYTK). Vanguard Group reported 1.80 million shares or 0% of all its holdings. Wasatch holds 1.75M shares or 0.25% of its portfolio. Blackrock Institutional Tru Na accumulated 1.11 million shares or 0% of the stock. Wade G W & last reported 0.03% of its portfolio in the stock. Acuta Prtnrs Limited Liability Corporation accumulated 140,969 shares or 0.64% of the stock. Fortaleza Asset Mgmt, a Illinois-based fund reported 15,930 shares. Tudor Corp Et Al reported 16,470 shares or 0% of all its holdings.
More important recent Cytokinetics, Inc. (NASDAQ:CYTK) news were published by: Globenewswire.com which released: “Cytokinetics, Inc. Reports Third Quarter 2016 Financial Results” on October 27, 2016, also Fool.com published article titled: “Why Cytokinetics, Inc. Got Hammered Today”, Marketwatch.com published: “/quotes/zigman/3870025/realtime” on December 21, 2009. More interesting news about Cytokinetics, Inc. (NASDAQ:CYTK) was released by: Globenewswire.com and their article: “Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results” with publication date: July 28, 2016.
CYTK Company Profile
Cytokinetics, Incorporated, incorporated on August 5, 1997, is a late-stage biopharmaceutical company. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Firm is developing small molecule drug candidates, which are specifically engineered to increase muscle function and contractility. The Company’s drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.